Literature DB >> 21357714

Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Mario Cazzola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21357714      PMCID： PMC3046263          DOI： 10.3324/haematol.2010.030023

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  33 in total

1.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

Authors:  Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B Glassman; Maher Albitar; Monica I Kwari; Miloslav Beran
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Molecular basis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Andreas Reiter; Rosangela Invernizzi; Nicholas C P Cross; Mario Cazzola
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 3.  Prognostic classification and risk assessment in myelodysplastic syndromes.

Authors:  Mario Cazzola; Luca Malcovati
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.

Authors:  Silvia Bresolin; Marco Zecca; Christian Flotho; Luca Trentin; Andrea Zangrando; Laura Sainati; Jan Stary; Barbara de Moerloose; Henrik Hasle; Charlotte M Niemeyer; Geertruy Te Kronnie; Franco Locatelli; Giuseppe Basso
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

5.  Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.

Authors:  Matteo Giovanni Della Porta; Luca Malcovati
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

6.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

7.  Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Authors:  Martin Jädersten; Leonie Saft; Andrea Pellagatti; Gudrun Göhring; James S Wainscoat; Jacqueline Boultwood; Anna Porwit; Brigitte Schlegelberger; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

8.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors:  Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

9.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.

Authors:  Kiyoyuki Ogata; Matteo G Della Porta; Luca Malcovati; Cristina Picone; Norio Yokose; Akira Matsuda; Taishi Yamashita; Hideto Tamura; Junichi Tsukada; Kazuo Dan
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

10.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Authors:  Esther Zipperer; Daniela Pelz; Kathrin Nachtkamp; Andrea Kuendgen; Corinna Strupp; Norbert Gattermann; Rainer Haas; Ulrich Germing
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941
View more
  10 in total

1.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Authors:  Luca Malcovati; Matteo G Della Porta; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Kathrin Nachtkamp; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

2.  Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.

Authors:  Massimo Breccia; Vincenzo Federico; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

3.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

4.  Prognostic factors in myelodysplastic syndromes.

Authors:  Irina Triantafyllidis; Anca Ciobanu; Oana Stanca; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2012-12

Review 5.  There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rami S Komrokji
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 6.  Refractory thrombocytopenia and neutropenia: a diagnostic challenge.

Authors:  Emmanuel Gyan; François Dreyfus; Pierre Fenaux
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-18       Impact factor: 2.576

7.  Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes.

Authors:  Tatjana Sotirova; Aleksandar Stojanovic; Sonja Genadieva-Stavric; Svetlana Krstevska; Dejan Spasovski; Trajan Balkanov
Journal:  Mater Sociomed       Date:  2014-10-29

8.  The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.

Authors:  Sergio Matarraz; Cristina Teodosio; Carlos Fernandez; Manuel Albors; María Jara-Acevedo; Antonio López; María Gonzalez-Gonzalez; María Laura Gutierrez; Juan Flores-Montero; Carlos Cerveró; Marlies Pizarro-Perea; María Paz Garrastazul; Gonzalo Caballero; Oliver Gutierrez; Guy Daniel Mendez; Manuel González-Silva; Paula Laranjeira; Alberto Orfao
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

9.  Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases.

Authors:  Masahiro Ono; Reiko J Tanaka; Manabu Kano; Toshio Sugiman
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

Review 10.  Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes.

Authors:  Jean A Ridgeway; Sara Tinsley; Sandra E Kurtin
Journal:  J Adv Pract Oncol       Date:  2017-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.